Mitral Valve Surgery
10
1
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
40%
4 trials in Phase 3/4
13%
1 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR
Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture
Methylene Blue-Enhanced Ultrafiltration Improves Outcomes After Cardiopulmonary Bypass
Post-market Safety and Performance Outcomes of the VIVERE® Bovine Pericardial Bioprosthetic Valve
Registry for Mitral Valve Surgery at Department of Cardiac Surgery University Hospital of Basel/ Switzerland
Serratus Anterior Plane Block for Minimal Invasive Cardiac Surgery
The Role of Left Atrial Fibrosis in Mitral Valve Repair Surgery (ALIVE Trial)
Comparative Study Between Conventional Crystalloid Cardioplegic Solution With Modified Del Nido Cardioplegia
PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension
Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass